Alzheimer’s Disease Progression May Be Faster in Women, Study Suggests
New research indicates that women with Alzheimer’s disease may experience a more rapid decline in cognitive function than men, particularly when certain proteins are present in the brain. The findings, released on Saturday, March 7, 2026, highlight the complex interplay between biological sex and neurodegenerative disease progression, and could have implications for diagnosis and treatment strategies.
Researchers at the Mayo Clinic analyzed data from 415 volunteers diagnosed with Alzheimer’s disease, monitoring changes in their brains over time. The study focused on the presence of two key proteins: tau, which is known to disrupt communication between nerve cells and contribute to cognitive decline, and alpha-synuclein, a protein more commonly associated with Parkinson’s disease. The presence of both proteins appears to be a critical factor in the observed differences.
To detect abnormal alpha-synuclein levels, researchers analyzed cerebrospinal fluid. Accumulation of the tau protein was assessed using brain imaging techniques. Approximately 17% of the participants showed signs of abnormal alpha-synuclein accumulation.
The research revealed that among patients with elevated levels of both tau and alpha-synuclein, brain changes occurred up to 20 times faster in women compared to men. This suggests that the co-occurrence of these two proteins may have a disproportionately detrimental effect on women’s cognitive health.
“The findings suggest that the presence of alpha-synuclein could be associated with a faster progression of dementia Alzheimer’s in women,” researchers stated.
These findings align with growing evidence that neurodegenerative diseases do not affect all patients equally, and that biological differences between men and women can significantly influence disease development and progression. Understanding these differences is crucial for developing targeted therapies and improving patient outcomes.
